Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Ptc Therapeutics (PTCT) over the last 5 years, with Q1 2025 value amounting to $2000.0.

  • Ptc Therapeutics' Deferred Taxes rose 30000.0% to $2000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was -$55.9 million, marking a year-over-year decrease of 1914.04%. This contributed to the annual value of -$55.9 million for FY2024, which is 1913.91% down from last year.
  • As of Q1 2025, Ptc Therapeutics' Deferred Taxes stood at $2000.0, which was up 30000.0% from -$55.9 million recorded in Q4 2024.
  • In the past 5 years, Ptc Therapeutics' Deferred Taxes registered a high of $4.0 million during Q4 2023, and its lowest value of -$55.9 million during Q4 2024.
  • In the last 3 years, Ptc Therapeutics' Deferred Taxes had a median value of -$2000.0 in 2023 and averaged -$11.4 million.
  • In the last 5 years, Ptc Therapeutics' Deferred Taxes tumbled by 150512.69% in 2024 and then surged by 30000.0% in 2025.
  • Over the past 3 years, Ptc Therapeutics' Deferred Taxes (Quarter) stood at $4.0 million in 2023, then crashed by 1505.13% to -$55.9 million in 2024, then surged by 100.0% to $2000.0 in 2025.
  • Its Deferred Taxes stands at $2000.0 for Q1 2025, versus -$55.9 million for Q4 2024 and -$3000.0 for Q3 2024.